Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoo, Kwai Han | - |
dc.contributor.author | Yoon, Dok Hyun | - |
dc.contributor.author | Kang, Hye Jin | - |
dc.contributor.author | Lee, Won Sik | - |
dc.contributor.author | Kim, Kihyun | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Kim, Jeong-A | - |
dc.contributor.author | Kim, Sung-Hyun | - |
dc.contributor.author | Kwak, Jae-Yong | - |
dc.contributor.author | Kim, Yang Soo | - |
dc.contributor.author | Min, Chang-Ki | - |
dc.contributor.author | Lee, Je-Jung | - |
dc.contributor.author | Yoon, Sung-Soo | - |
dc.contributor.author | Suh, Cheolwon | - |
dc.contributor.author | Baz, Rachid | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.date.accessioned | 2022-03-27T07:40:25Z | - |
dc.date.available | 2022-03-27T07:40:25Z | - |
dc.date.created | 2021-09-13 | - |
dc.date.issued | 2022-02 | - |
dc.identifier.issn | 0147-0272 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/83829 | - |
dc.description.abstract | Lenalidomide and low-dose dexamethasone (Rd) are a standard treatment for older adults with multiple myeloma (MM). Lenalidomide monotherapy has rarely been evaluated for newly diagnosed transplant-ineligible MM patients. This multicenter phase II trial evaluated a response-adapted strategy for elderly patients with newly diagnosed MM without high-risk features. Patients were administered single-agent lenalidomide for the first 21 days of two 28-day cycles. Patients with progressive disease received Rd. The primary endpoint was progression-free survival using the uniform response assessment from the International Myeloma Working Group. Of the 34 enrolled patients, 28 were included in the efficacy analysis. The overall response rate (ORR, ≥ partial response [PR]) to single-agent lenalidomide or lenalidomide plus prednisone was 64.3%. Ten patients received Rd after disease progression, with an Rd ORR of 70%. The ORR of response-adapted lenalidomide-based therapy was 75%. After the median follow-up of 35.6 months, the median progression-free survival was 33.5 months (95% confidence interval [CI], 16.9-50.2), and the median overall survival was 51.8 months (95% CI, 22.0-81.6). The most common adverse event was neutropenia (46.7%), and 17 patients (56.7%) experienced infection including pneumonia. Response-adapted lenalidomide-based therapy was feasible in newly diagnosed, transplant-ineligible MM patients without high-risk features. © 2021 | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MOSBY-ELSEVIER | - |
dc.relation.isPartOf | Current Problems in Cancer | - |
dc.title | Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000760343200009 | - |
dc.identifier.doi | 10.1016/j.currproblcancer.2021.100788 | - |
dc.identifier.bibliographicCitation | Current Problems in Cancer, v.46, no.1 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85114265923 | - |
dc.citation.title | Current Problems in Cancer | - |
dc.citation.volume | 46 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Yoo, Kwai Han | - |
dc.contributor.affiliatedAuthor | Lee, Jae Hoon | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Corticosteroids | - |
dc.subject.keywordAuthor | Lenalidomide | - |
dc.subject.keywordAuthor | Myeloma | - |
dc.subject.keywordAuthor | Older adults | - |
dc.subject.keywordAuthor | Response-adapted therapy | - |
dc.subject.keywordPlus | BORTEZOMIB PLUS MELPHALAN | - |
dc.subject.keywordPlus | SINGLE-AGENT LENALIDOMIDE | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | DEXAMETHASONE | - |
dc.subject.keywordPlus | PREDNISONE | - |
dc.subject.keywordPlus | DARATUMUMAB | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | SAFETY | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.